Equibles does not estimate personal net worth.
Get an email with a short summary when Summit Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get SMMT alertsMahkam Zanganeh is recorded as Board Member at Summit Therapeutics Inc. (SMMT) since January 1, 2020, CEO and COO at Summit Therapeutics Inc. (SMMT) and Board Member at Pulse Biosciences, Inc. (PLSE) since January 1, 2017. The newest filing on record that lists Mahkam Zanganeh as CEO and Board Member at Summit Therapeutics Inc. (SMMT) is dated April 17, 2026. The newest filing on record that lists Mahkam Zanganeh as COO at Summit Therapeutics Inc. (SMMT) is dated April 29, 2021. Pulse Biosciences, Inc. reported in an 8-K filed August 12, 2024 that Mahkam Zanganeh was appointed member of the Strategic Advisory Committee, effective August 9, 2024. The proxy statement of Summit Therapeutics Inc. reports total compensation of $246,047,279 for Mahkam Zanganeh in fiscal 2025, including a base salary of $616,500. Disclosed compensation is on record for 6 fiscal years. Mahkam Zanganeh has spoken on 3 earnings calls across 1 company, most recently for Summit Therapeutics Inc. on May 1, 2024. Summit Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Pulse Biosciences, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Summit Therapeutics Inc. includes Glyn Edwards (CEO), Robert Duggan (CEO and Board Member), Manmeet Soni (CFO and Board Member) and 7 others.
“the Board also appointed Directors Mahkam Zanganeh and Manmeet Soni as members of the Strategic Advisory Committee.”
“As Bob mentioned, we remain incredibly enthusiastic about the accomplishments of Team Summit only one year into our partnership with Akeso.”
“I'm incredibly enthusiastic about ivonescimab, its potential and what we have already accomplished. In the past 6 months since we closed our deal with Akeso in January, we have held interactions, including 3 large meetings, with the FDA surrounding 3 separate non-small cell lung cancer indications.”
“I'm incredibly enthusiastic about our collaboration with Akeso. Akeso has a rich and diversified antibody drug pipeline with over 30 internally discovered drug candidates in various stages of development, including 6 bispecific antibodies.”
SEC 8-K
2024-08-09–present
2020-01-01–present
Last confirmed April 17, 2026
2017-01-01–present
Last confirmed May 11, 2026
Start not stated–present
Last confirmed April 17, 2026
Start not stated–present
Last confirmed April 29, 2021
2017-01-01–2021-10-04
Biotechnology · Healthcare
CEO, COO, Board Member
2020-01-01–present
Medical Instruments & Supplies · Healthcare
Board Member
2017-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Summit Therapeutics Inc. (SMMT) | Co-Chief Executive Officer, President and Director | $616,500 | $246,047,279 |
| 2024 | Summit Therapeutics Inc. (SMMT) | Co-Chief Executive Officer, President and Director | $600,000 | $1,161,021 |
| 2023 | Summit Therapeutics Inc. (SMMT) | Co-Chief Executive Officer, President and Director | $600,000 | $20,562,924 |
| 2022 | Summit Therapeutics Inc. (SMMT) | Co-Chief Executive Officer, President and Director | $450,000 | $1,242,049 |
| 2021 | Summit Therapeutics Inc. (SMMT) | Director, Chief Executive Officer, and President | $450,000 | $9,639,214 |
| 2020 | Summit Therapeutics Inc. (SMMT) | Director, co-Chief Executive Officer, and President | $49,615 | $527,312 |
